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Abstract: The reproducibility crisis has led to an increasing number of repli-
cation studies being conducted. Sample sizes for replication studies are of-
ten calculated using conditional power based on the effect estimate from the
original study. However, this approach is not well suited as it ignores the
uncertainty of the original result. Bayesian methods are used in clinical tri-
als to incorporate prior information into power calculations. We propose to
adapt this methodology to the replication framework and promote the use of
predictive instead of conditional power in the design of replication studies.
Moreover, we describe how extensions of the methodology to sequential clin-
ical trials can be tailored to replication studies. Conditional and predictive
power calculated at an interim analysis are compared and we argue that pre-
dictive power is a useful tool to decide whether to stop a replication study
prematurely. A recent project on the replicability of social sciences is used to
illustrate the properties of the different methods.
Key Words: Replication Studies, Conditional Power, Predictive Power, Se-
quential Design, Interim Analysis.
1 Introduction
The replicability of research findings is essential for the credibility of science. However, the scientific world
is experiencing a crisis (Begley and Ioannidis, 2015) as the replicability rate of many fields appears to be
alarmingly low. As a result, large scale replication projects, where original studies are selected and repli-

























Collaboration, 2015), social sciences (Camerer et al., 2018) and economics (Camerer et al., 2016) among oth-
ers. Replication success is usually assessed using significance and p-values, compatibility of effect estimates,
subjective assessments of replication teams and meta-analysis of effect estimates (e. g. in Open Science Col-
laboration, 2015). The statistical evaluation of replication studies is still generating much discussion and
new standards are proposed (e. g. in Patil et al., 2016; Ly et al., 2018; Held, 2020).
Yet before a replication study is analyzed, it needs to be designed. While the conditions of the replication
study are ideally identical to the original study, the replication sample size stands out as an exception
and requires further consideration. Using the same sample size as in the original study may lead to a
severely underpowered replication study, even if the effect θ̂o estimated in the original study is the true,
unknown effect size θ (Goodman, 1992). Standard power calculations using the effect estimate from the
original study as the basis for the replication study are commonly used. A major criticism of this method
is that the uncertainty accompanying this original finding is ignored and so the resulting replication study
is likely to be underpowered (Anderson and Maxwell, 2017). In this paper, we propose alternatives based
on predictive power and adapted from Bayesian approaches to incorporate prior knowledge to sample size
calculation in clinical trials (Spiegelhalter et al., 2004).
In an era where an increasing number of replication projects are being undertaken, optimal allocation
of resources appears to be of particular importance. Adaptive designs are well suited for this purpose and
their relevance no longer needs to be justified, particularly in clinical trials where continuing a study which
should be stopped can be a matter of life or death. Stopping for futility refers to the termination of a trial
when the data at interim indicate that it is unlikely to achieve statistical significance at the end of the trial
(Snapinn et al., 2006). In contrast, stopping for efficacy arises when the data at interim are so convincing
that there is no need to continue collecting more data. One approach for assessing efficacy and futility is
called stochastic curtailment (Halperin et al., 1982), where the conditional power of the study, given the data
so far, is calculated for a range of alternative hypotheses. Instead of conditional power, predictive power
can also be used to judge if a trial should be continued (Herson, 1979). This concept has been discussed in
depth in Dallow and Fina (2011) and Rufibach et al. (2016), with an emphasis on the choice of the prior in
the latter.
Lakens (2014) points out that sequential replication studies could be an alternative to fixed sample size
calculations. This approach has been adopted by Camerer et al. (2018) in the Social Science Replication Project
(SSRP), a large-scale project aiming at evaluating the replicability of social sciences experiments published
between 2010 and 2015 in Nature and Science. A two-stage procedure was used and 21 original studies have
been replicated. However, the sequential approach did not include a power calculation at interim, only
allowed for a premature stopping for efficacy and did not mention any adjustment on the threshold for
significance. We try to fill this gap by proposing different methods to calculate the interim power, namely
the power of a replication study taking into account the data from an interim analysis. We argue that
predictive interim power is a useful tool to guide the decision to stop replication studies where the intended
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effect is not present. Our framework only enables power calculation at a single interim analysis.
This paper is structured as follows: power calculations for non-sequential (Section 2) and sequential
(Section 3) replication studies are presented, with a focus on comparing conditional and predictive methods.
Relevant properties of these methods are then illustrated using data from the SSRP in Section 4. We close
with some discussion in Section 5.
2 Non-sequential replication studies
Suppose a study has been conducted in order to estimate an unknown effect size θ. We consider the one-
sample case throughout this paper but the results can also be generalized to the case of two samples. The
study produced a positive effect estimate θ̂o. In order to confirm this finding, a replication study is planned.
Let us assume that the future data of the replication study are normally distributed as follows,






where σ is the known standard deviation of one observation, assumed to be the same for original and
replication study. In the SSRP, as well as in most replication projects, power calculations for the replication









centered around θ̂o and with variance inversely proportional to the original sample size no (Spiegelhalter
et al., 2004). Prior (1) may be too optimistic in practice, where original effect estimates tend to be exagger-
ated (Camerer et al., 2018). This issue and possible solutions are discussed in the next section.
In what follows, the different formulas resulting from the use of the prior (1) are described. This section
is inspired by Section 6.5 in Spiegelhalter et al. (2004) where Bayesian contributions to selecting the sample
size of a clinical trial are studied. We adapt this methodology to the replication framework and express the
power calculation formulas in terms of unitless quantities (namely relative sample sizes and test statistics).
2.1 Methods
We differentiate between design and analysis prior, both having an impact on the power calculation (O’Hagan
and Stevens, 2001), and present the different combinations of priors in Table 1.
A point prior at θ = θ̂o in the design corresponds to the concept of conditional power (Spiegelhalter
and Freedman, 1986). In contrast, the normal design prior (1) is related to the concept of predictive power,
which averages the conditional power over the possible values of the true effect according to its design
prior distribution. Alternative names in the literature are assurance (O’Hagan et al., 2005), probability of
study success (Wang et al., 2013) and Bayesian predictive power (Spiegelhalter et al., 1986). Conditional and
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Table 1: Methods of power calculations resulting from the different combinations of design and analysis priors.
Design
























predictive power are usually accompanied by a flat analysis prior, but can also be calculated assuming that
original and replication data are pooled (using the normal analysis prior (1)), resulting in the conditional
Bayesian power and the fully Bayesian power, respectively.
In practice, publication bias and the winner’s curse often lead to overestimated original effect estimates
(Ioannidis, 2008; Button et al., 2013; Anderson and Maxwell, 2017). Hence, prior (1) might be over-optimistic
and lead to underpowered replication studies. A simple way to correct for this over-optimism is to multiply
the design prior mean θ̂o in (1) by a factor d between 0 and 1. The corresponding shrinkage factor s = 1− d
can be chosen based on previous replication studies in the same field. This is the approach considered in
the SSRP and we expand on this in Section 4. More advanced methods using empirical Bayes based power
estimation (Jiang and Yu, 2016) and data-driven shrinkage (Pawel and Held, 2020) are not considered here.
2.1.1 Conditional power
Conditional power is the probability that a replication study will lead to a statistically significant conclusion
at the two-sided level α, given that the alternative hypothesis is true (Spiegelhalter et al., 2004, Section 2.5).
In the context of a replication study, the alternative hypothesis is represented by the effect estimate θ̂o from
the original study.
Let zα/2 and Φ[·] respectively denote the α/2-quantile and the cumulative distribution function of the










see Appendix A.1 for a derivation. The required replication sample size nr can be obtained by rearranging
(2).
A key feature of our framework is that all power/sample size formulas are expressed without absolute
effect measures. Simple mathematical rearrangements produce an expression which only depends on the
original test statistic to = θ̂o/σo = θ̂o
√
no/σ and the variance ratio c = σ2o/σ2r which simplifies to the relative
sample size c = nr/no and represents how much the sample size in the replication study is increased as
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compared to the one in the original study. Formula (2) then becomes
CP = Φ
[√
c to + zα/2
]
. (3)
This formula highlights an intuitive property of the conditional power: the larger the evidence in the origi-
nal study (quantified by to) or the larger the increase in sample size compared to the original study (repre-
sented by c), the larger the conditional power of the replication study.
2.1.2 Predictive power
In order to incorporate the uncertainty of θ̂o, the concept of predictive power is discussed (Spiegelhalter













see Appendix A.2 for a derivation. The predictive power (4) tends to the conditional power (3) as the orig-











2.1.3 Fully Bayesian and conditional Bayesian power
So far two power calculation methods where a flat analysis prior is used have been considered. This ap-
proach corresponds to the two-trials rule in drug development, which requires “at least two adequate and
well-controlled studies, each convincing on its own, to establish effectiveness” (FDA, 1998, p. 3). In practice,
this translates to two studies with a significant p-value and an effect in the intended direction.
An alternative approach for the analysis is to pool original and replication data. This is similar to a meta-
analysis of original and replication effect estimates, as done in the SSRP for example. However, in order
to ensure the same evidence level as when original and replication studies are analyzed independently, the
corresponding two-sided significance level α̃ = α2/2 should be used (Fisher, 1999; Gibson, 2020).
The fully Bayesian power is calculated using the prior (1) in both the design and the analysis. Using
the same prior beliefs in both stages is considered as the most natural approach by some authors (e. g. in












Note that the fully Bayesian power is also a predictive power as it incorporates the uncertainty of the
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original effect estimate θ̂o.












Derivations of (6) and (7) can be found in Appendix A.4 and A.3.
2.2 Properties
For fixed relative sample size c and two-sided level α, all four formulas (3), (5), (6) and (7) react to an
increase in original test statistic to with a monotone increase in power. However, the original result cannot
be changed and it is more realistic to study the power when varying the relative sample size c for fixed
original test statistic to instead. Consider two original studies with p-values 0.046 and 0.005. These p-values
correspond to the original studies by Duncan et al. (2012) and Shah et al. (2012) in the SSRP dataset and are










































Figure 1: CP, PP, FBP and CBP as a function of the relative sample size c for two original studies with
po = 0.046 (left) and po = 0.005 (right) at the two-sided α = 5% level, so α̃ = 0.00125. The vertical grey line
corresponds to the intersection of CP and PP curves as calculated in (8), and the vertical black line to the
intersection of FBP and CBP as in (9). The horizontal black line indicates the asymptote 1− po/2 of PP and
FBP.
2.2.1 Conditional vs. predictive power
The power obtained with predictive methods is always closer to 50% than the power obtained with condi-
tional methods (Spiegelhalter et al., 2004; Grouin et al., 2007; Dallow and Fina, 2011). In practice, power is
typically larger than 50% and this implies that CP (3) is larger than PP (5); and CBP (7) is larger than FBP
6
(6).
Furthermore, it can be shown that CP and PP are both equal to 50% if the relative sample size is
c = z2α/2/t2o , (8)
the squared α/2-quantile of the normal distribution divided by the squared test statistic from the original
study (see Appendix A.5 for details). Equation (8) implies that the larger the evidence in the original study
(quantified by to), the smaller the relative sample size c where CP and PP curves intersect.
This can be observed in Figure 1, where the relative sample size at the intersection of the CP and PP
curves is closer to zero in the replication of a convincing original study (po = 0.005, c = 0.48) than in the
replication of a borderline original study (po = 0.046, c = 0.96). Likewise, FBP and CBP are crossing at a
power of 50% with corresponding relative sample size
c = z2α̃/2/t2o − 1 . (9)
2.2.2 Predictive power cannot always reach 100%
Unlike CP (3) which always reaches 100% for a sufficiently large replication sample size, PP (5) has an
asymptote at 1 − po/2. This means that the more convincing the original study, the closer to 100% the PP
of an infinitely large replication study is. In a sense, the original result penalizes the predictive power.
However, this penalty is not very stringent, as replication of an original study with a two-sided p-value
of 0.05 would still be able to reach a PP of 97.5% for a sufficiently large replication sample size. This
property also applies to the FBP and can be observed in Figure 1 where the horizontal black line indicates
the asymptote 1− po/2.
2.2.3 Pooling original and replication studies
For a borderline significant original study (e.g. po = 0.046 in Figure 1), FBP (6) and CBP (7) are respectively
always smaller than PP (5) and CP (3). In contrast, when the original study is more convincing (e.g. po =
0.005 in Figure 1), FBP is larger than PP (respectively CBP larger than CP) for some values of c. However, if
po < α̃, the level required at the end of the replication study (typically α̃ = 0.00125), FBP and CBP converge






for increasing c and then increase to 1 − po/2 (FBP) or 100% (CBP). See Appendix A.6 for a derivation. A
highly convincing original study will thus always have FBP and CBP very close to 100% independently of
the sample size. This implies that a replication may not be required at all, a clear disadvantage of pooling
original and replication studies instead of considering them independently.
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3 Sequential replication studies
In Section 2, power calculations are performed before any data have been collected in the replication study.
This framework is extended in this section and allows power (re)calculation at an interim analysis, after
some data have been collected in the replication study already. The interim power is defined as the prob-
ability of statistical significance at the end of the replication study given the data collected so far. The
incorporation of prior knowledge into interim power has been studied in Spiegelhalter et al. (2004, Section
6.6) and we adapt this approach to the case where prior information refers to a single original study. More-
over, the power calculation formulas are expressed in terms of unitless quantities (relative sample sizes and
test statistics) in the following. It is well known from the field of clinical trials that the maximum sample
size (if the trial has not been stopped at interim) increases with the number of planned interim analyses
(Matthews, 2006, Section 8.2.1). In order to maintain a given power, even one interim analysis requires a
larger maximum sample size than for a trial with a fixed size and the calculation of the replication sample
size should take this into account.
3.1 Methods
In addition to the point prior θ = θ̂o and the normal prior (1), the new framework enables the specification
of a flat design prior. Table 2 shows the different types of interim power calculations that are investigated
in this section.
Table 2: Methods of interim power calculations resulting from different design priors using a flat analysis prior.
Design











Calculating the interim power to detect the effect estimate from the original study ignores the uncer-
tainty of the original result. This corresponds to the conditional power in Table 2. Uncertainty of the
original result can be taken into account when recalculating the power at an interim analysis, turning the
conditional power into a predictive power. This requires the selection of a prior distribution for the true
effect, which is updated by the data collected so far in the replication study. The prior distributions dis-
cussed here are the normal prior (1) (leading to the informed predictive power) and a flat prior (leading to
the predictive power). The conditional power is then averaged with respect to the posterior distribution of
the true effect size, given the data already observed in the replication study. A pooled analysis of original
and replication data can also be considered in this framework but is omitted here.
Let θ̂i be the effect estimate at interim and σ2i = σ2/ni the corresponding variance, with ni the sample
size at interim. The sample size that is still to be collected in the replication study is denoted by nj and
the total replication sample size is thus nr = ni + nj . The interim power formulas can be shown to only
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depend on the original and interim test statistics to and ti = θ̂i/σi, the relative sample size c = nr/no and
the variance ratio f = σ2r/σ2i = ni/nr, the fraction of the replication study already completed.
3.1.1 Conditional power at interim
The conditional power at interim is the interim power to detect the effect θ = θ̂o. It can be expressed as
CPi = Φ
[√
c(1− f) to +
√
f






see Appendix B.1 for a derivation. In the particular case where no data has been collected yet in the replica-
tion study (f = 0), the CPi (11) reduces to the CP (3). Interim power can also be calculated to detect θ = θ̂i,
this is however not recommended (Bauer and König, 2006; Kunzmann et al., 2020).
3.1.2 Informed predictive power at interim





(cf + 1)(1 + c) to +
√
f(1 + c)
(1− f)(cf + 1) ti +
√
cf + 1
(1 + c)(1− f) zα/2
]
, (12)
see Appendix B.2 for a derivation. In the case of f = 0 (no data collected in the replication study so far),
the IPPi (12) reduces to the PP (5). By considering the original result but also its uncertainty, the predictive
power at interim is a compromise between considering only the original effect estimate (CPi) and ignoring
the original study completely (PPi).
3.1.3 Predictive power at interim
The predictive power at interim is the predictive interim power using a flat design prior. In other words,










see Appendix B.3 for a derivation. Note that PPi (13) corresponds to FBP (6) provided that the original study
in FBP formula is considered as the interim study (see Appendix B.3). This illustrates the dependence of
original and replication studies when a normal prior is used in the analysis.
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3.2 Properties
Theoretical and specific properties of the conditional, informed predictive and predictive power at interim
are discussed.
3.2.1 Conditional vs predictive power
The power at interim, as compared to study start, involves two additional parameters, namely the test
statistic ti from the interim analysis and the fraction f of the replication study already conducted. It is
therefore not straightforward to compare the different methods in terms of which one results in a larger
power. Comparison is facilitated if certain assumptions are made. Consider any combination of a signifi-
cant original result, a non-significant interim result and a replication sample size at least twice as large as
the original sample size. This translates to to > z1−α/2, ti < z1−α/2 and c ≥ 2 in formulas (11), (12) and (13).
Under these assumptions and with f > 0.25, the CPi is always larger than the IPPi, which is always larger
than the PPi, see Appendix B.4. However, one has to be careful as these conditions are sufficient, but not
necessary for obtaining this order.
3.2.2 Weights given to original and interim results
Equations (11), (12) and (13) can be expressed as Φ[x] where x is a weighted average of to, ti and zα/2 with
weights wo, wi and wα, say. The weights wo and wi depend on the relative sample size c and the fraction f
of the replication study already completed.
In the CPi formula (11), an increase in c leads to a monotone increase in wo and does not affect wi. In
other words, the weight given to the original result in the CPi becomes larger if the relative sample size c
increases. Furthermore, the larger the fraction f of the replication study already completed, the less weight
is given to the original result and conversely, the more weight to the interim result.
In the IPPi formula (12), an increase in f leads to a decrease in wo and an increase in wi. Only if the
interim analysis takes place early will the original result have a greater weight than the interim result in the
calculation of the IPPi, see Appendix B.5.
In the PPi formula (13), no weight is given to the original result and the weight wi given to interim
results increases when f increases.
3.2.3 A power of 100% cannot always be reached with the predictive methods
Considering that an interim analysis has been conducted, ni and ti are fixed, and the only parameter that
can vary is the sample size nj still to be collected in the replication study. Increasing this sample size results
in an increase of the relative sample size c and a decrease of the fraction f of the replication study already
completed. If nj is large enough, the CPi (11) reaches 100%. In contrast, the asymptotes of IPPi (12) and
PPi (13) are penalized by the original and/or interim results. The larger the evidence in the original study
and at interim (represented by to and ti, respectively), the larger the asymptote of the IPPi (formula given
10
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Figure 2: CPi, IPPi and PPi as a function of the sample size nj still to be collected in the replication study
(or equivalently, as a function of the fraction of the replication study still to be completed (1 − f ) and the
relative sample size c) for an original study with po = 0.005 and with two hypothetical interim p-values
pi = 0.04 (left) and pi = 0.5 (right). The two-sided level α is 0.05. Horizontal dashed lines represent the
asymptotes of IPPi and PPi and the horizontal dotted line represents the minimum PPi.
in Appendix B.6). The asymptote of the PPi, on the other hand, is 1 − pi/2. This last property is explained
in Dallow and Fina (2011, Section 4) and the asymptotes can be visualized in Figure 2 for an original study
with po = 0.005 and two hypothetical interim results: pi = 0.04 and pi = 0.5. On the left panel, the
asymptotes of CPi, IPPi and PPi are all close to 100% as original and interim p-values are fairly small. A
large increase in interim p-value hardly has an effect on the asymptote of the IPPi (from 99.98% to 99.5%,
right panel) but results in a dramatic decrease of the asymptote of the PPi and remarkably, the maximum
PPi achievable for a study with an interim p-value of 0.5 is only 75%.
3.2.4 Non-monotonicity property of power
If the two-sided interim p-value is not significant (pi > α), the interim power with all three methods behaves
in an expected way: it increases with increasing sample size nj . However, this property breaks when pi < α.
In this situation, the power assuming no additional subject to be added (f = 1) is 100%, declines with
increasing nj (decreasing f ) and then increases. For example, the minimum predictive power at interim




which means that the PPi of any replication study with a significant
interim result will never be smaller than 50% (details in Appendix B.7). This property can be observed
in Figure 2 (left panel) where the PPi cannot be smaller than 73%. Dallow and Fina (2011) explain this
characteristic as follows: “Intuitively, if the interim results are very good, any additional subject can be




Twenty-one significant original findings were replicated in the SSRP and a two-stage procedure was adopted.
In stage 1, the replication studies had 90% power to detect 75% of the original effect estimate. Data collec-
tion was stopped if a two-sided p-value< 0.05 and an effect in the same direction as the original effect were
found. If not, data collection was continued in stage 2 to have 90% power to detect 50% of the original effect
estimate for the first and second data collections pooled. The shrinkage factor s was chosen to be 0.5 as a
previous replication project in the psychological field (Open Science Collaboration, 2015) found replication
effect estimates on average half the size of the original effect estimates. Stages 1 and 2 can be considered as
two steps of a sequential analysis, with an interim analysis in between. The analysis after stage 1 will be
called the interim analysis while the final analysis will refer to the analysis based on the pooled data from
stages 1 and 2.
The complete SSRP dataset with extended information is available at https://osf.io/pfdyw/. The
effects are given as correlation coefficients, making them easily interpretable and comparable. Moreover,
the application of Fisher’s z transformation z(r) = tanh−1(r) to the correlation coefficients justifies an
asymptotic normal distribution and the standard error of the transformed coefficients becomes a function
of the effective sample size n−3 only, se(z) = 1/
√
n− 3. In this dataset, original effects are always positive.
A ready-to-use dataset SSRP can be found in the package ReplicationSuccess, available at https:
//r-forge.r-project.org/projects/replication/.
4.1 Descriptive results
The results are displayed in Figure 3. Twelve studies were significant at interim with an effect in the correct
direction but by mistake only eleven were stopped. Out of the ten studies that were continued, only two
showed a significant result in the correct direction at the final analysis. The study that was wrongly con-
tinued turned out to be non-significant at the final analysis. The effect of publication bias is clearly seen:
original effect estimates are larger than the corresponding replication effect estimates for 19 out of the 21
studies and are on average twice as large.
4.2 Power calculations
The methods described in Sections 2 and 3 are used to calculate the power of the 21 replication studies
before the onset of the study and at the interim analysis. Because our calculations are based on Fisher’s
z-transformed correlation coefficients, the effective sample sizes are used. The relative sample size is then
c = (nr − 3)/(no− 3) and the fraction f of the replication study already completed f = (ni− 3)/(nr − 3). A
two-sided α = 5% level is used as in the original paper, so α̃ = 0.00125 in the calculation of FBP and CBP.
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Not significant at final
Figure 3: Original effect estimate vs. replication effect estimate (on the correlation scale). Replications
which were not pursued in stage 2 are included with the results from stage 1. Shape and color of the point
indicate whether the study was stopped due to a significant result in the correct direction at interim (green
triangle), was significant in the correct direction at the final analysis (red circle) or was not significant at the
final analysis (black square). The diagonal line indicates replication effect estimates equal to original effect
estimates.
4.2.1 At the replication study start
We computed the CP, PP, FBP and CBP of the 21 replication studies. The replication sample size that we
considered in the calculations is the one used by the authors of the SSRP in stage 1, ignoring stage 2. To be
consistent with the procedures of the SSRP, a shrinkage factor s of 0.25 was used in the calculations. Results
can be found in Figure 4, where some properties discussed in Section 2.2 are illustrated. CP is larger than
PP for all studies, and similarly CBP is larger than FBP as expected (see Section 2.2.1). Furthermore, it can
be oberved that for some studies FBP is larger than PP, while it is the opposite for some other studies. This
depends on the p-value po from the original study and the relative sample size c as explained in Section 2.2.3.
The same applies to CP and CBP but cannot be directly observed in Figure 4.
4.2.2 At the interim analysis
Replication studies which did not reach significance after the first data collection were continued. We have
selected these studies and calculated their interim power with the different methods (see Table 3). These
studies have a sample size substantially larger in the replication as compared to the original study (large
c). Moreover, the interim analysis took place in the second quarter of the replication study (0.3 ≤ f ≤ 0.47)















CP PP FBP CBP
Figure 4: CP, PP, FBP and CBP of the 21 studies of the SSRP at level α = 5% (so α̃ = 0.00125 for FBP and
CBP) using a shrinkage factor s of 0.25 in the calculations. Each circle represents a study and the lines link
the same studies.
(2010) which was continued by mistake). Excluding this study, they all fulfill the sufficient conditions
mentioned in Section 3.2.1 and follow the order CPi > IPPi > PPi. This also hold for the particular study
with a significant interim result as the corresponding relative sample size c is large (c = 11.62).
The CPi is remarkably large for all studies, even for the five studies where the interim effect estimate
is in the opposite direction as the original estimate as the weight given to the significant original result is
consequent due to the large relative sample size c (see Section 3.2.2). In contrast, more weight is given to
the interim as compared to the original result in the IPPi formula, making the corresponding IPPi values
more sensible. If a futility boundary between 10% and 30% had been used (as in DeMets (2006)) four out of
the eight studies which failed to replicate at the final analysis would have been stopped at interim based on
the IPPi values. Surprisingly, the replication study of Ramirez and Beilock (2011) presents a relatively large
IPPi (61.4%) although the interim result goes in the opposite direction as the original result. This is due to
the very small original p-value. The PPi of the same study is considerably smaller (4.2%) since the original
result does not influence the power with this method. Furthermore, six out of eight studies which failed
to replicate at the final analysis would have been stopped at interim if futility stopping had been decided
based on a PPi of less than 30%. Significant interim results lead to large PPi values (see Section 3.2.4), and
that can observed for the study that was incorrectly continued.
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Table 3: CPi, IPPi and PPi of the ten studies that were continued including the original, interim and replication two-
sided p-values and effect estimates, the relative sample size c and the fraction f of the replication study already com-
pleted.
Original Interim Interim power Replication
Study po ro f pi ri CPi IPPi PPi c pr rr
Duncan 0.005 0.67 0.37 0.29 0.18 100.0 74.6 43.4 7.42 0.00001 0.44
Pyc 0.023 0.38 0.43 0.09 0.15 100.0 85.3 71.0 9.18 0.009 0.15
Ackerman 0.048 0.27 0.43 0.02 0.14 100.0 95.0 90.3 11.69 0.125 0.06
Rand 0.009 0.14 0.47 0.37 0.03 99.8 51.9 27.0 6.27 0.234 0.03
Ramirez 0.000008 0.79 0.30 0.72 -0.08 100.0 61.4 4.2 4.47 0.390 -0.10
Gervais 0.029 0.29 0.42 0.41 -0.05 97.5 1.9 0.3 9.78 0.415 -0.04
Lee 0.013 0.39 0.42 0.45 -0.07 97.7 3.1 0.4 7.65 0.435 -0.05
Sparrow 0.002 0.37 0.44 0.27 0.11 99.7 74.1 40.1 3.50 0.451 0.05
Kidd 0.012 0.27 0.40 0.27 -0.07 98.9 1.6 0.1 8.57 0.467 -0.03
Shah 0.046 0.27 0.45 0.15 -0.09 87.0 0.1 0.0 11.62 0.710 -0.02
5 Discussion
Conditional power calculations appear to be the norm in most replication projects. In this paper, we have
drawn attention to notable shortcomings of this approach and outlined the rationale and properties of pre-
dictive power. We encourage researchers to abandon conditional methods in favor of predictive methods
which make a better use of the original study and its uncertainty.
Furthermore, as many replications are being conducted and only a fraction confirms the original result,
we argue for the necessity of sequentially analyzing the results. With this in mind, we encourage the
initiative from Camerer et al. (2018) to terminate some replication studies prematurely based on an interim
analysis. However, their approach only enables efficacy stopping. We propose to use interim power to
judge if a replication study should be stopped for futility. Interim analyses can help to save time and
resources but also raise new questions with regard to the choice of prior distributions. We have shown using
studies from the SSRP that different design priors lead to very different power values and by extension to
different decisions. Conditioning the power calculations at interim on the original results is even more
unreasonable than at the study start and leads to very large power values given a significant original result,
even if interim results suggest evidence in the opposite direction. We recommend the use of IPPi and PPi
to make futility decisions. A 30% futility boundary is sometimes employed in clinical trials and has proved
to be reasonable in the SSRP. Efficacy stopping based on interim power is known to inflate the type-I error
rate (Jennison and Turnbull, 1999, Chapter 10). We only consider futility stopping as this issue does not
apply here (Lachin, 2005).
Some limitations should be noted. First, the paper discusses power calculations before the onset of the
study and at an interim analysis separately. However, the planned interim analysis has an impact on power
at study start and sample size adjustments are necessary (Wassmer and Brannath, 2016, Section 2.1.2). This
is nevertheless rarely done in current replication projects such as SSRP. Second, while the ICH E9 ‘Statistical
Principles for Clinical Trials’ (ICH E9 Expert Working Group, 1999) recommends blinded interim results,
our data at interim are assumed to be unblinded. This is not a problem for the one-sample case but becomes
an issue when we want to compare two groups. Such a situation would require an Independent Data
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Monitoring Committee to prevent the replication study from being biased (Kieser and Friede, 2003). Third,
the assumption of normally distributed observations is made.
Further research will focus on extending this framework to multiple interim analyses in a replication
study and to sequentially conducted replication studies. It will also be of interest to apply the concept of
interim power discussed in Section 3 to the reverse-Bayes assessment of replication success (Held, 2020).
Software
Software for these power calculations can be found in the R-package
ReplicationSuccess, available at https://r-forge.r-project.org/projects/replication/.
An example of the usage of this package is given in Appendix C.
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A Non-sequential replication study
A.1 Conditional power (CP)






Let us suppose the null hypothesis of the replication study is H0: θ = 0 and we want to detect an alter-
native hypothesis H1: θ = θ̂o > 0, where θ̂o is the effect estimate of the original study. The corresponding
standardized test statistic tr isYnr
√
nr/σ and we declare the result statistically significant at the two-sided





small for θ̂o > 0.






Following notation from Spiegelhalter et al. (2004, Section 6.5.2), this event is denoted by SCα/2. The condi-
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Setting θ = θ̂o in (15) gives the CP formula (2).
A.2 Predictive power (PP)
Predictive power is computed by integrating (15) with respect to the prior (1). Integration can be demanding




2 (1/no + 1/nr)
)
, (16)

























A.3 Conditional Bayesian power (CBP)
‘Bayesian significance’ is denoted as
SBα̃/2 = Pr (θ < 0 | replication data) < α̃/2 .




no + nrzα̃/2σ − noθ̂o
nr
,
see Spiegelhalter et al. (2004, Section 6.5.3) for details.



























Setting θ = θ̂o in (17) gives
Pr
(















A.4 Fully Bayesian power (FBP)































A.5 Conditional vs. predictive power




































⇔ nr = 0 or nr =
σ2z2α/2
θ̂2o

























because zα/2 is always negative and θ̂o is assumed to be positive.
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− 1 . (20)
By plugging the equation (20) in the FBP (or CBP) formula (6), we once again retrieve a power of 50%.
A.6 Minimum fully Bayesian power




































By setting it to 0 and solving for nr, we obtain the replication sample size nr needed to reach the minimum





































B Sequential replication studies
B.1 Conditional power at interim (CPi)











a significant result is found at then end of the replication study if
Ynj >
−√ni + njzα/2σ − niθ̂i
nj
,
denoted by SCα/2. Additional details are provided in Spiegelhalter et al. (2004, Section 6.6.3). The conditional
power at interim is
Pr
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Setting θ = θ̂o in (21) gives
Pr
(

















B.2 Informed predictive power at interim (IPPi)
Informed predictive power at interim is computed by integrating (21) with respect to the posterior distri-
bution obtained by combining the prior (1) and the data collected so far in the replication study. The IPPi
can be expressed as
Pr
(











ni (no + ni + nj)






(ni + nj) (no + ni)




B.3 Predictive power at interim (PPi)



















Equation (24) is identical to (19) given that ni = no, nj = nr and θ̂i = θ̂o.
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B.4 The ordering of different types of interim power


























zα/2 ≥ 0 . (25)
If to > z1−α/2, ti < z1−α/2 and c > 2, equation (25) holds for every 0 < f < 1.
The IPPi (12) is greater than (or equal to) the PPi (13) if
√
(1− f)c
















zα/2 ≥ 0 . (26)
If to > z1−α/2, ti < z1−α/2 and c > 2, equation (26) holds for 0.25 < f < 1.
B.5 Weights given to original and interim results









In the PPi formula (12), wo > wi if
√
c(1− f)
(cf + 1)(1 + c) >
√
f(1 + c)
(1− f)(cf + 1)
⇔ f < c
2 −
√
c2 + 6c+ 1c−
√
c2 + 6c+ 1 + 4c+ 1
2c .
Figure 5 shows the conditions on f so that wo > wi as a function of c.
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Figure 5: Maximum fraction f of the replication study already completed so that wo > wi in formulas (11)
(CPi) and (12) (IPPi).
B.6 Asymptote of IPPi















As the PPi formula in (24) is identical to the fully Bayesian power formula in (19) with ni = no, nj = nr and







# install the package
install.packages("ReplicationSuccess",
repos = "http://R-Forge.R-project.org")
# load the package
library("ReplicationSuccess")
Data
# load the data
data(SSRP)
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Table 4: Main variables of the SSRP dataset.
study Authors of the original paper
ro Original effect on correlation scale
ri Interim effect on correlation scale
rr Replication effect on correlation scale
fiso Original effect on Fisher-z scale
fisi Interim effect on Fisher-z scale
fisr Replication effect on Fisher-z scale
se_fiso Standard error of fiso
se_fisi Standard error of fisi
se_fisr Standard error of fisr
no Nominal sample size in original study
ni Nominal sample size in replication study at interim
nr Nominal sample size in replication study at the final analysis
po Two-sided p-value from original study
pi Two-sided p-value from interim analysis
pr Two-sided p-value from replication study
Table 4 shows the main variables of the SSRP dataset.
Functions
The two main functions that were used in this paper are powerSignificance and powerSignificanceInterim.
The main arguments of these functions are presented in Table 5.
Table 5: Arguments of the powerSignificance and powerSignificanceInterim functions. Arguments only
used in powerSignificanceInterim are in grey.
zo z-value from original study
zi z-values from interim analysis
c Ratio of the replication sample size to the original sample size
f Fraction of the replication study already completed
designPrior Design prior
analysisPrior Analysis prior
alternative Direction of the alternative
level Significance level




# z-value from original study
SSRP$zo = SSRP$fiso/SSRP$se_fiso
# z-value at interim
SSRP$zi = SSRP$fisi/SSRP$se_fisi
# relative sample size from figure 4,
# where stage 2 is ignored
# (results at interim are considered
# final results)
SSRP$c_f3 = (SSRP$ni - 3)/(SSRP$no - 3)
# same values can be found
# with variance ratio
# SSRP$c_f3 = SSRP$se_fiso^2/SSRP$se_fisi^2
# relative sample size
SSRP$c = (SSRP$nr - 3)/(SSRP$no - 3)
# same values with variance ratio
# SSRP$c = SSRP$se_fiso^2/SSRP$se_fisr^2
# fraction of replication study
# already completed
SSRP$f = (SSRP$ni - 3)/(SSRP$nr - 3)
# same result
# with variance ratio
# SSRP$f = SSRP$se_fisr^2/SSRP$se_fisi^2
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# Example: calculation of the informed predictive power
# at interim (IPPi) from Table 3
# select the studies that were continued






designPrior = "informed predictive",
analysisPrior = "flat",
alternative = "two.sided",
level = 0.05)
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